Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
OBJECTIVE
To report the external ocular changes in 2 patients receiving epidermal growth factor receptor (EGFR) inhibitors.


METHODS
Retrospective observational case series. Two patients receiving epidermal growth factor inhibitors for metastatic non-small-cell lung carcinoma were followed clinically and with external photographs.


RESULTS
Findings included acneiform facial changes, telangiectasia of eyelid margins, meibomitis, tear film dysfunction, and unusual, hyperpigmented, tortuous eyelashes.


CONCLUSIONS
EGFR inhibitors used in the treatment of certain malignancies can lead to symptomatic adnexal and ocular surface changes. Ophthalmologists should be aware of these to appropriately manage them.
Zhang
Grace
G
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Basti
Surendra
S
Jampol
Lee M
LM
D017486:Acneiform Eruptions / Q000139:chemically induced*; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D001762:Blepharitis / Q000139:chemically induced*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005140:Eyelashes / Q000187:drug effects*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D006983:Hypertrichosis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects*; D012189:Retrospective Studies
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib